The A1chieve study: A 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice

Diabetes Research and Clinical Practice

Volumn 88, Issue SUPPL. 1, 2010, Pages S11-S16

  Shah, Siddharth N ^a   Litwak, León ^b   Haddad, Jihad ^c   Chakkarwar, Praful N ^d   Hajjaji, Issam ^e  

^a SL Raheja Hospital   (India)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c Endocrinology Section   (Jordan)

^d Novo Nordisk FemCare AG   (Switzerland)

^e National Centre for Diabetes and Endocrinology   (Libyan Arab Jamahiriya)

Author keywords

A1chieve; Insulin; Observational study; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; CLINICAL PROTOCOL; INTERNATIONAL COOPERATION; PROSPECTIVE STUDY;

CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONAL COOPERATION; PROSPECTIVE STUDIES;

EID: 77952692097     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(10)70003-6     Document Type: Article

References (22)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359:1577-1589.
3. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373(9677):1765-1772.
4. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52(11):2288-2298.
5. IDF Clinical Guidelines Task Force Global guideline for Type 2 diabetes 2005, International Diabetes Federation, Brussels.
6. Saydah SH, Fradkin J, Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
7. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann. Intern. Med. 2006, 144:465-474.
8. Elgrably F, Costagliola D, Chwalow AJ, Varenne P, Slama G, Tchobroutsky G Initiation of insulin treatment after 70 years of age: patient status 2 years later. Diabet. Med. 1991, 8:773-777.
9. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005, 28:2673-2679.
10. Korytkowski M When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord. 2002, 26(Suppl 3):S18-S24.
11. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007; Apr 18, 2. CD005613. 10.1002/14651858.CD005613.pub3.
12. Bazzano LA, Lee LJ, Reynolds K, Jackson JA, Fonseca V Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet. Metab. 2008, 25:924-932.
13. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 2006, 28:1569-1581.
14. Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res. Clin. Pract. 2010, (in preparation).
15. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General assembly, Tokyo 2004.
16. Brooks R EuroQol: the current state of play. Health Policy 1996, 37:53-72.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 2008, 61:344-349.
18. Niskanen L, Virkamäki A, Hansen JB, Saukkonen T Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: Evidence from the PREDICTIVE study. Diabetes Res. Clin. Pract. 2009, 86:e15-e18.
19. Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int. J. Clin. Pract. 2007, 61:523-528.
20. Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, et al. IMPROVE Study Group Expert Panel. The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int. J. Clin. Pract. 2008, 62:1809-1819.
21. Shestakova M, Bech OM, Momani MS Study design and baseline characteristics of patients in the PRESENT study. Diabetes Res. Clin. Pract. 2008, 81(Suppl 1):S3-S9.
22. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 2007, 357:1716-1730.